secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001437749-24-017651
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics appoints Troy Ignelzi to board as Audit Committee Chair
------------------------------------------------------------------------------

- Troy Ignelzi appointed as Class I director and Chair of Audit Committee, effective May 20, 2024.
- Evert Schimmelpennink stepped down from Audit Committee; Class I directors now Ignelzi and Olivia Ware.
- Ignelzi is CFO of Rapport Therapeutics; previously CFO at Karuna Therapeutics, scPharma, Juventas.
- Ignelzi will receive standard non-employee director compensation including an option for 23,150 shares.
- Board determined Ignelzi independent and an audit committee financial expert under SEC/Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924017651/0001437749-24-017651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924017651/cont20240420_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer